Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL  
53.28
-1.34 (-2.45%)
Regulatory, Earnings Announcements

Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data On Zn-C3 (Wee1i) And Zn-C5 (Serd) And Two Potentially Registrational Trials For Zn-C3

Published: 06/28/2021 12:31 GMT
Zentalis Pharmaceuticals Inc (ZNTL) - Zentalis Pharmaceuticals Announces Updates Across Its Pipeline Including Promising New Interim Clinical Data on Zn-c3 (wee1i) and Zn-c5 (serd) and Two Potentially Registrational Trials for Zn-c3, With the First Trial Already Initiated.
Zentalis Pharmaceuticals - Reports Additional Zn-c3 Phase 1 Interim Monotherapy Data.
Zentalis Pharmaceuticals - Zn-c3 Phase 1 Interim Monotherapy Data Showed Increased Tumor Reduction & Durability in Exceptional Responder Population.
Zentalis Pharmaceuticals - Potential Accelerated Approval Path Identified for Monotherapy Use of Zn-c3 in Usc Following End-of-phase 1 FDA Meeting.
Zentalis Pharmaceuticals - to Seek FDA Guidance on Potentially Registrational Trial for Tumor-agnostic, Novel Predictive Biomarker-enabled Zn-c3 Trial.
Zentalis Pharmaceuticals - Zn-c5 Phase 1 Interim Data Supports Its Potential Safety & Tolerability Profiles in Monotherapy & in Combinations.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.13

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.12

More details on our Analysts Page.